Fresenius Medical Care AG & Co. KGaA (FMEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fresenius Medical Care AG & Co. KGaA (FMEA) has a cash flow conversion efficiency ratio of 0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€226.89 Million ≈ $265.25 Million USD) by net assets (€14.20 Billion ≈ $16.61 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Fresenius Medical Care AG & Co. KGaA fund operations to measure how many days the company can operate on defensive assets alone.
Fresenius Medical Care AG & Co. KGaA - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Fresenius Medical Care AG & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fresenius Medical Care AG & Co. KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fresenius Medical Care AG & Co. KGaA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Groep Brussel Lambert NV
BR:GBLB
|
0.038x |
|
Harmony Gold Mining Company Limited
F:HAM
|
0.066x |
|
CPFL Energia S.A
SA:CPFE3
|
0.060x |
|
Mineral Resources Ltd
AU:MIN
|
0.209x |
|
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
|
0.002x |
|
Shandong Sinocera Func Material
SHE:300285
|
0.037x |
|
KOC HOLDING ADR/5 TN 1
F:KRKA
|
N/A |
|
James Hardie Industries plc
F:JHA
|
0.031x |
Annual Cash Flow Conversion Efficiency for Fresenius Medical Care AG & Co. KGaA (2016–2025)
The table below shows the annual cash flow conversion efficiency of Fresenius Medical Care AG & Co. KGaA from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Fresenius Medical Care AG & Co. KGaA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €14.28 Billion ≈ $16.70 Billion |
€2.68 Billion ≈ $3.13 Billion |
0.188x | +24.04% |
| 2024-12-31 | €15.77 Billion ≈ $18.44 Billion |
€2.39 Billion ≈ $2.79 Billion |
0.151x | -14.65% |
| 2023-12-31 | €14.83 Billion ≈ $17.33 Billion |
€2.63 Billion ≈ $3.07 Billion |
0.177x | +26.38% |
| 2022-12-31 | €15.45 Billion ≈ $18.06 Billion |
€2.17 Billion ≈ $2.53 Billion |
0.140x | -21.22% |
| 2021-12-31 | €13.98 Billion ≈ $16.34 Billion |
€2.49 Billion ≈ $2.91 Billion |
0.178x | -48.12% |
| 2020-12-31 | €12.33 Billion ≈ $14.42 Billion |
€4.23 Billion ≈ $4.95 Billion |
0.343x | +76.89% |
| 2019-12-31 | €13.23 Billion ≈ $15.46 Billion |
€2.57 Billion ≈ $3.00 Billion |
0.194x | +21.43% |
| 2018-12-31 | €12.90 Billion ≈ $15.08 Billion |
€2.06 Billion ≈ $2.41 Billion |
0.160x | -21.05% |
| 2017-12-31 | €10.83 Billion ≈ $12.66 Billion |
€2.19 Billion ≈ $2.56 Billion |
0.202x | +14.14% |
| 2016-12-31 | €10.89 Billion ≈ $12.74 Billion |
€1.93 Billion ≈ $2.26 Billion |
0.177x | -- |
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arr… Read more